ReviewBMC medicine2013
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness.
Review in BMC medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03152409 (Salicylic Augmentation in Depression), which is not on this map. Cited by 88 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Salicylic Augmentation in Depression
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 392 citations in OpenAlex.
- Association between aspirin use and risk of dementia: a systematic review and meta-analysis.European geriatric medicine · 2024Pooled it
- Exploration of key drug target proteins highlighting their related regulatory molecules, functional pathways and drug candidates associated with delirium: evidence from meta-data analyses.BMC geriatrics · 2023Pooled it
- Brain Inflammatory Marker Abnormalities in Major Psychiatric Diseases: a Systematic Review of Postmortem Brain Studies.Molecular neurobiology · 2023Pooled it
- Acetylsalicylic acid (aspirin) for schizophrenia.The Cochrane database of systematic reviews · 2019Pooled it
- Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial.Molecular psychiatry · 2021Trial
- Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial.JAMA psychiatry · 2020Trial
- Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.BMC medicine · 2020Trial
- Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study.Translational psychiatry · 2019Trial
- ASPREE-D: Aspirin for the prevention of depression in the elderly.International psychogeriatrics · 2016Trial
- The use of statins for the treatment of depression in patients with acute coronary syndrome.Translational psychiatry · 2015Trial
- Host-directed treatments for tuberculous meningitis utilizing a multi-platform approach across mouse and human models.Nature communications · 2026Article
- Does Administration of Low-Dose Aspirin Enhance the Efficacy of Psychotropic Drugs in Patients with Bipolar Disorder, Schizophrenia, and Schizoaffective Disorder?Pharmaceuticals (Basel, Switzerland) · 2026Article
- Host-directed treatments for tuberculous meningitis: A multi-platform approach across mouse and human models.Research square · 2026Article
- Contributions of Pharmacovigilance to the Understanding of Risks Associated with Ibuprofen: Descriptive and Disproportionality Analysis Using FAERS Data.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Unlocking neuronal health: leveraging C. elegans for drug repurposing studies.Cell communication and signaling : CCS · 2026Review
- Study of the effect of zinc oxide nanoparticles coated with salicylic acid on intra-abdominal adhesions in rats.BMC gastroenterology · 2025Article
- Pharmacovigilance Insights into Ibuprofen's Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Aspirin's Role in Reducing Oxidative Stress: Implications for Cognition and Heart Function in Autism Spectrum Disorder.Veterinary medicine international · 2025Article
- Effects of low-dose aspirin in bipolar disorder: study protocol for a randomised controlled trial (the A-Bipolar RCT).BMJ open · 2024Article
- Breaking free from the inflammatory trap of depression: Regulating the interplay between immune activation and plasticity to foster mental health.Neuroscience applied · 2024Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is compelling evidence to support an aetiological role for inflammation, oxidative and nitrosative stress (O&NS), and mitochondrial dysfunction in the pathophysiology of major neuropsychiatric disorders, including depression, schizophrenia, bipolar disorder, and Alzheimer's disease (AD). These may represent new pathways for therapy. Aspirin is a non-steroidal anti-inflammatory drug that is an irreversible inhibitor of both cyclooxygenase (COX)-1 and COX-2, It stimulates endogenous production of anti-inflammatory regulatory 'braking signals', including lipoxins, which dampen the inflammatory response and reduce levels of inflammatory biomarkers, including C-reactive protein, tumor necrosis factor-α and interleukin (IL)--6, but not negative immunoregulatory cytokines, such as IL-4 and IL-10. Aspirin can reduce oxidative stress and protect against oxidative damage. Early evidence suggests there are beneficial effects of aspirin in preclinical and clinical studies in mood disorders and schizophrenia, and epidemiological data suggests that high-dose aspirin is associated with a reduced risk of AD. Aspirin, one of the oldest agents in medicine, is a potential new therapy for a range of neuropsychiatric disorders, and may provide proof-of-principle support for the role of inflammation and O&NS in the pathophysiology of this diverse group of disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.